Thornburg Investment Management Inc. Grows Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

Thornburg Investment Management Inc. increased its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 279.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 746,218 shares of the company’s stock after buying an additional 549,378 shares during the period. Thornburg Investment Management Inc. owned about 0.25% of Stevanato Group worth $13,690,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Natixis Advisors L.P. lifted its holdings in Stevanato Group by 1.9% in the 4th quarter. Natixis Advisors L.P. now owns 23,858 shares of the company’s stock valued at $651,000 after purchasing an additional 449 shares in the last quarter. Personal CFO Solutions LLC lifted its holdings in Stevanato Group by 4.6% in the 4th quarter. Personal CFO Solutions LLC now owns 12,186 shares of the company’s stock valued at $333,000 after purchasing an additional 534 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Stevanato Group by 54.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,089 shares of the company’s stock valued at $84,000 after acquiring an additional 1,086 shares during the last quarter. Hilltop National Bank increased its stake in shares of Stevanato Group by 34.3% during the 2nd quarter. Hilltop National Bank now owns 4,395 shares of the company’s stock valued at $81,000 after acquiring an additional 1,122 shares during the last quarter. Finally, Raymond James Trust N.A. increased its stake in shares of Stevanato Group by 18.7% during the 2nd quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock valued at $188,000 after acquiring an additional 1,613 shares during the last quarter.

Wall Street Analyst Weigh In

STVN has been the subject of a number of research analyst reports. Morgan Stanley dropped their price objective on shares of Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Citigroup dropped their target price on shares of Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of €30.60 ($33.63).

Stevanato Group Stock Up 0.4 %

Shares of NYSE:STVN opened at €20.20 ($22.20) on Thursday. The company has a quick ratio of 1.13, a current ratio of 1.74 and a debt-to-equity ratio of 0.19. Stevanato Group S.p.A. has a 52-week low of €16.56 ($18.20) and a 52-week high of €35.56 ($39.08). The company has a 50 day moving average of €20.31 and a two-hundred day moving average of €23.37. The company has a market capitalization of $5.97 billion, a price-to-earnings ratio of 36.73, a price-to-earnings-growth ratio of 6.06 and a beta of 0.59.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported €0.09 ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.10 ($0.11) by (€0.01) (($0.01)). Stevanato Group had a net margin of 11.27% and a return on equity of 10.89%. The firm had revenue of €259.60 million during the quarter, compared to analyst estimates of €254.92 million. During the same period last year, the business earned $0.15 EPS. The firm’s revenue was up 1.7% compared to the same quarter last year. As a group, analysts forecast that Stevanato Group S.p.A. will post 0.51 earnings per share for the current fiscal year.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.